India has earned its place as pharmacy of the world. It's also fast emerging as a hub for clean mobility. But it's lacking leadership in innovation because of institutional reasons. Two regulators - Central Drugs Standard Control Organisation (CDSCO) and Bureau of Energy Efficiency (BEE) - have not kept pace with the industries they oversee. Both are overly bureaucratic and lack the will to be innovative. And both the sectors they govern have become an imperative for India's growth story.
India manufactures roughly a fifth of the world's generic medicines. Yet, in 2023, it accounted for less than 2% of global first-in-class drug launches, China and the US together claiming about 60%. The gap is not in shortage of capital or talent, but in the regulator's scientific capacity.